Lansoprazole 3 mg/mL Suspension
Advertisement

Loyd V. Allen, Jr., PhD
Professor Emeritus
College of Pharmacy,
University of Oklahoma
Oklahoma City

Method of Preparation:
Calculate the quantity of each ingredient for the amount to be prepared. Accurately weigh or measure each ingredient. Hold the neck of the bottle containing the lansoprazole powder and tap the bottom edges on a hard surface to loosen the powder. Remove the cap from the bottle. Tap the top of the induction seal liner to loosen any powder adhering to the liner. Carefully and slowly peel back the inner foil seal liner from the bottle. Using the enclosed tool, scrape any lansoprazole powder from the seal into the bottle. Using the smaller end of the tool, with firm strength loosen any powder from the inside lower edges of the bottle. It is important to ensure that no lansoprazole powder remains trapped in the inside lower edges of the bottle. Again using the tool, distribute the lansoprazole powder evenly over the bottom surface of the bottle. Shake the FIRST-PPI Suspension bottle for a few seconds. Open the FIRST-PPI Suspension bottle and empty about one-half of its contents into the lansoprazole powder bottle. Replace the cap and shake the lansoprazole powder bottle for approximately 60 seconds. Shake vigorously. Empty the remaining FIRST-PPI Suspension into the lansoprazole powder bottle. Allow the suspension to drain for 10 seconds. Replace the cap and shake the lansoprazole powder bottle vigorously for approximately 60 seconds. Package and label.

Note: If appropriate, dispense the enclosed adapter cap and oral syringe with accompanying instructions for use. The adapter cap is not child resistant.

Use:
Lansoprazole is indicated to treat conditions related to gastric and duodenal ulcers.

Packaging:
Package in the containers in which it is provided and compounded.

Labeling:
Keep out of reach of children. Keep refrigerated. Shake well before each use. Discard after ____ [time period].

Stability:
A beyond-use date of not more than 30 days when stored at refrigerated temperature may be used.

Quality Control:
Quality-control assessment can include weight/volume, pH, specific gravity, active drug assay, color, rheologic properties, physical observation, and physical stability (discoloration, foreign materials, gas formation, mold growth).

Discussion:
Lansoprazole (Prevacid, C16H14F3N3O2S, MW 369.36) occurs as a white to brownish-white powder that is sparingly soluble in ethanol and practically insoluble in water. The degradation rate of the compound in aqueous solution increases with decreasing pH.

The commercially manufactured product (Prevacid) is supplied as delayed-release capsules and as SoluTabs, available in two dosage strengths: 15 mg and 30 mg of lansoprazole per tablet. Many clinical situations require the use of a different dose or a liquid lansoprazole oral suspension, as presented here. Read more.

How Pharmacists Are Adapting to USP <795>
During COVID-19


Tyler A. Goins, PharmD, MSHA, BCPS
Assistant Manager of Inpatient Sterile Compounding and Childrens Hospital Clinical Operations
UVA Health System
Richmond, Virginia


Patient care is in a continual state of change, and pharmacy practice must reinvent itself to keep up with dynamic times. The coronavirus disease 2019 (COVID-19) pandemic has increased the rate of that change and has forced pharmacists and other healthcare professionals to adapt more quickly. Pharmaceutical compounding provides a prime example of the need to stay updated with new evidence and evolving requirements that keep patients and healthcare professionals safe. Compounding is the creation of customized medications for specific patients that should be prepared in an appropriate environment to maintain safety and effectiveness. Pharmacies across the country are looking for new ways to stay ahead of potential contamination, supply shortages, and uncertain times.

Pharmacists are relied on to have expertise in medication compounding and the guidelines that govern compounding practice. U.S. Pharmacopeia General Chapter <795> (USP <795>) addresses extemporaneous compounding of pharmaceuticals and defines what constitutes good compounding practices. The complexity of compounding guidance can be difficult for pharmacy staff to adhere to, especially those who do not perform extemporaneous compounding on a routine basis. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App